CD3-CM101-100μg / 询价
CD3-CM101-500μg / 询价
CD3-CM101-500μgx2 / 询价
- 客服电话
- 技术支持
Cynomolgus CD3E&CD3D/CD3 epsilon&CD3 delta Protein
Recombinant Cynomolgus CD3E&CD3D or CD3 epsilon&CD3 delta protein is expressed from HEK293 with His tag and Flag tag at the C-Terminus.It contains Gln22-Asp117 (CD3E)&Phe22-Ala105 (CD3D) [Accession | Q95LI5.2(CD3E)&Q95LI8(CD3D)].
The protein has a predicted MW of 11.93 kDa (CD3E) and 10.55 kDa (CD3D). Due to glycosylation, the protein migrates to 13-20 kDa based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE; >95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus CD3E&CD3D on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus CD3E&CD3D is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus CD3E&CD3D, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD3 Antibody, hFc Tag with the EC50 of 5.6 ng/ml determined by ELISA (QC Test).
T-cell surface glycoprotein CD3 epsilon&CD3 delta chain, also known as CD3E&CD3D, are single-pass type I membrane proteins. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain.
CD3; CD3e; CD3E; CD3d; T3D; CD3D; CD3E&CD3D; CD3 delta&CD3 epsilon
(1) Penaranda C , Tang Q , Bluestone J A. Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells[J]. The Journal of Immunology, 2011, 187(4):2015-2022.
